Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
RELEVANCE data sheds light on follicular lymphoma treatment
Morschhauser F et al. N Engl J Med. 2018;379:934-47.
Key clinical point: Rituximab plus lenalidomide was as effective as rituximab with chemotherapy but with a different safety profile.
Major finding: Complete responses were seen in 48% of rituximab/lenalidomide patients versus 53% in the rituximab/chemotherapy patients (P = .13).
Study details: A phase 3 superiority trial of 1,030 patients with previously untreated follicular lymphoma.
Disclosures: Celgene and the Lymphoma Academic Research Organization funded the study. The authors reported various disclosures, including financial ties to Celgene.
Citation:
Morschhauser F et al. N Engl J Med. 2018;379:934-47.